Novo Nordisk Pill Launch Drives Record Sales and Guidance Upgrade

Blockbuster Debut Shatters Expectations

Novo Nordisk's weight-loss pill has delivered one of the most successful pharmaceutical launches in recent memory, generating $353.6 million in revenue during its first quarter on the market. The oral version of Wegovy, which launched in January, brought in roughly twice the analyst expectations of $182 million , sending the Danish drugmaker's stock soaring and prompting an immediate upgrade to its annual outlook.

The numbers tell a remarkable story of market demand. More than 2 million prescriptions have been written for the Wegovy pill since its January 5 launch, marking the strongest-ever GLP-1 volume launch in the US . Weekly prescriptions have surged past 200,000, while more than 1 million patients have used the pill in just four months.

This explosive growth has allowed Novo Nordisk to capture a commanding position in the obesity market. CEO Mike Doustdar revealed that Wegovy now commands 65% of all new prescriptions in the U.S. , a dramatic turnaround for a company that had been losing ground to rival Eli Lilly.

Strategic Advantage in Competitive Landscape

The timing of Novo's success couldn't be more critical. Analysts see the weight-loss market growing to $100 billion by the end of the decade , making market share battles increasingly consequential. Novo got a head start in the oral GLP-1 market, introducing Wegovy about three months before Lilly launched its competing pill option, Foundayo .

That head start is paying dividends. The Wegovy pill had more than 18,000 prescriptions in its first full week on the market, compared with 5,612 prescriptions for Foundayo in the third week after its April 9 introduction . The disparity reflects not just timing advantages but also clinical performance, as patients on the Wegovy pill lost a higher percentage of body weight in Novo's clinical trials than those in Lilly's testing of Foundayo .

Perhaps most encouraging for Novo, the pill isn't cannibalizing sales of its injectable products. CEO Doustdar noted that people are using both forms, creating "not cannibalizations, but a synergetic effect" between the pill and injection versions.

Financial Turnaround and Raised Guidance

The pill's success has prompted Novo to upgrade its 2026 financial outlook. The company now expects adjusted sales and profit to contract between 4% and 12% on a currency-adjusted basis, an improvement on the previously projected decline of between 5% and 13% . While still projecting declines, the improved guidance reflects the company's confidence in its obesity franchise momentum.

First-quarter results showed the broader impact of this success. Sales jumped 32% on a constant currency basis to reach $15.2 billion, while operating profit surged 65% , though these figures were boosted by a one-time accounting adjustment. More tellingly, obesity care sales reached $3.3 billion, up 22% at constant exchange rates .

The market response has been swift and positive. Novo's shares rose 6.7% in morning trading in Copenhagen , reflecting investor optimism about the company's competitive position in the lucrative weight-loss market.

Global Expansion on the Horizon

While the U.S. launch has exceeded all expectations, Novo is already planning the next phase of its pill rollout. Pending regulatory decisions, the first Wegovy pill launches outside the US are expected during the second half of 2026 , potentially opening new revenue streams in international markets where pricing dynamics may be more favorable.

The success comes at a crucial time for Novo, which had been struggling to maintain its early leadership in the GLP-1 space. Over the last year, Novo has overhauled its leadership, installed a new CEO and made plans to lay off 9,000 employees as it worked to regain competitive footing against Lilly's aggressive market expansion.

The Wegovy pill's record-breaking launch suggests that strategic pivot is working. As the obesity treatment market continues its explosive growth, Novo's early success with oral delivery could prove decisive in determining which company ultimately captures the largest share of this transformative healthcare opportunity.